Novartis

Premium price for Novartis' CAR-T sparks pushback from top PBM
Premium price for Novartis' CAR-T sparks pushback from top PBM
BioPharma Dive
Novartis
Kymriah
CAR-T
drug pricing
Express Scripts
PBMs
Flag link:
Two years on, Allergan’s $1.7B NASH drug still looks weak — at best
Two years on, Allergan’s $1.7B NASH drug still looks weak — at best
Endpoints
Allergan
NASH
Novartis
Cenicriviroc
Flag link:
Pharma executives wary of value-based deals, but see the potential benefits: PwC
Pharma executives wary of value-based deals, but see the potential benefits: PwC
Fierce Pharma
value-based contracts
Amgen
Novartis
Sanofi
Merck
Flag link:
New pharma CEOs to face payer, pricing challenges
New pharma CEOs to face payer, pricing challenges
Medical Marketing and Media
Pharma CEOs
Novartis
Teva Pharmaceutical
Kåre Schultz
Vasant Narasimham
payers
drug pricing
Flag link:
On CAR-T’s Edge, Seattle Researchers Plot to Bypass Novartis Therapy
On CAR-T’s Edge, Seattle Researchers Plot to Bypass Novartis Therapy
Xconomy
CAR-T
Novartis
Seattle Children's
pediatric cancer
ALL
gene therapy
Flag link:
Novartis touts 5-year Cosentyx data as it works to hold top spot in psoriasis
Novartis touts 5-year Cosentyx data as it works to hold top spot in psoriasis
Fierce Pharma
Novartis
Cosentyx
psoriasis
Flag link:
#ESMO17: Eli Lilly sets the stage for a CDK 4/6 showdown with Pfizer, Novartis — but not exactly to its advantage
#ESMO17: Eli Lilly sets the stage for a CDK 4/6 showdown with Pfizer, Novartis — but not exactly to its advantage
Endpoints
ESMO
Eli Lilly
Pfizer
Novartis
abemaciclib
breast cancer
Flag link:
An accurate analysis of the differences between Swiss companies Roche and Novartis
An accurate analysis of the differences between Swiss companies Roche and Novartis
GoInPharma
Novartis
Roche
Switzerland
Flag link:
Departing Novartis CEO Sets His Eyes On Silicon Valley
Departing Novartis CEO Sets His Eyes On Silicon Valley
Forbes
Pharma CEOs
Novartis
Joe Jimenez
Silicon Valley
Flag link:
Novartis charged much more in the U.S. for some drugs than in other countries
Novartis charged much more in the U.S. for some drugs than in other countries
Stat
Novartis
drug pricing
Flag link:
New Novartis CEO Narasimhan will face plenty of obstacles despite CAR-T triumph
New Novartis CEO Narasimhan will face plenty of obstacles despite CAR-T triumph
Fierce Biotech
Novartis
Pharma CEOs
Vas Narasimhan
CAR-T
Flag link:
Novartis follows up on big CAR-T win by naming Vas Narasimhan as its new CEO
Novartis follows up on big CAR-T win by naming Vas Narasimhan as its new CEO
Endpoints
Novartis
Pharma CEOs
CAR-T
Vas Narasimhan
Joe Jimenez
Flag link:
At $475,000, new cancer drug raises thorny questions about drug pricing — and value
At $475,000, new cancer drug raises thorny questions about drug pricing — and value
Stat
drug pricing
CAR-T
Novartis
Kymriah
Flag link:
Parkinson's Now a Hot Therapeutic Area: What's Up Lately?
Parkinson's Now a Hot Therapeutic Area: What's Up Lately?
Yahoo/Zacks.com
Parkinson's Disease
Novartis
Teva Pharmaceutial
UCB Pharma
MEDI1341
AstraZeneca
Takeda
PRX002
Prothena
Roche
Acorda
Inbrija
Adamas Pharmaceuticals
Gocovri
Flag link:
Novartis CEO: Here's How We Handled A Milestone In Pediatric Cancer
Novartis CEO: Here's How We Handled A Milestone In Pediatric Cancer
Forbes
Novartis
Pharma CEOs
Joe Jimenez
pediatrics
pediatric cancer
Flag link:
Landmark approval won, Novartis' next test is scaling CAR-T manufacturing
Landmark approval won, Novartis' next test is scaling CAR-T manufacturing
BioPharma Dive
Novartis
CAR-T
Kymriah
FDA
drug manufacturing
Flag link:
Profit on $475,000 Novartis cancer drug could be a while coming
Profit on $475,000 Novartis cancer drug could be a while coming
Yahoo/Reuters
Novartis
CAR-T
Kymriah
Flag link:
Why bluebird bio Inc Continued Its March Higher Again Today
Why bluebird bio Inc Continued Its March Higher Again Today
Motley Fool
Bluebird Bio
bb2121
CAR-T
Novartis
Kymriah
Gilead Sciences
Kite Pharma
Flag link:
Novartis $475,000 Price Tag Sets the Stage for a Price War With Gilead Sciences
Novartis $475,000 Price Tag Sets the Stage for a Price War With Gilead Sciences
Motley Fool
Novartis
CAR-T
Kymriah
Gilead Sciences
Kite Pharma
M&A
Flag link:
Novartis, UCSF researchers urge FDA to clean up its messy adverse events database
Novartis, UCSF researchers urge FDA to clean up its messy adverse events database
Endpoints
Novartis
FDA
adverse events
Flag link:

Pages